Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Orthofix Medical (OFIX) over the last 16 years, with Q3 2025 value amounting to -$427000.0.

  • Orthofix Medical's Gains from Investment Securities fell 12167.51% to -$427000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $847000.0, marking a year-over-year decrease of 9092.56%. This contributed to the annual value of $6.9 million for FY2024, which is 11408.63% up from last year.
  • Latest data reveals that Orthofix Medical reported Gains from Investment Securities of -$427000.0 as of Q3 2025, which was down 12167.51% from -$763000.0 recorded in Q2 2025.
  • Orthofix Medical's 5-year Gains from Investment Securities high stood at $3.1 million for Q2 2024, and its period low was -$10.7 million during Q2 2022.
  • Its 5-year average for Gains from Investment Securities is -$596444.4, with a median of -$595000.0 in 2025.
  • As far as peak fluctuations go, Orthofix Medical's Gains from Investment Securities tumbled by 58025.4% in 2022, and later soared by 34625.0% in 2024.
  • Quarter analysis of 5 years shows Orthofix Medical's Gains from Investment Securities stood at -$1.2 million in 2021, then rose by 17.83% to -$986000.0 in 2022, then surged by 350.1% to $2.5 million in 2023, then crashed by 72.02% to $690000.0 in 2024, then crashed by 161.88% to -$427000.0 in 2025.
  • Its Gains from Investment Securities was -$427000.0 in Q3 2025, compared to -$763000.0 in Q2 2025 and $1.3 million in Q1 2025.